Pharmacy Times®
Specialty Pharmacy Times
  • Hepatitis C on Track to Become a Rare Disease by 2036
  • FDA Accepts First Application in US for Biosimilar
  • The Updated HIV Prevention Guidelines
  • Study Supports Mammography in Women 75 Years and Older
  • Limited Market for Ebola Vaccine Hinders Development
  • Affordable Care Act Projected to Drive Up Prescription Drug Spending in Coming Years
Therapy in Development for Different Ebola Strains
Davy James, Associate Editor
Researchers seek to get ahead of potential future Ebola outbreaks.
Inflammatory Bowel Disease Drugs May Increase Leukemia Risk
Davy James, Associate Editor
Thiopurines found to increase the risk of myeloid disorders.
CVS Caremark Specialty Connect Provides Comprehensive Support
Program offers patients choice and flexibility in how they access their specialty medications, while providing centralized, expert clinical support.
Opsumit by Actelion Pharmaceuticals US, Inc
Michael R. Page, PharmD, RPh
Opsumit (macitentan) was approved to reduce the risk of hospitalization and delay disease progression in patients with WHO group I pulmonary arterial hypertension.
Zydelig by Gilead Sciences, Inc
Michael R. Page, PharmD, RPh
The FDA has approved Zydelig (idelalisib) tablets for the later-line treatment of 3 types of cancer, including chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.
Featured Video
The Evolution of the Mid-Size Specialty Pharmacy
Michael Nameth, RPh, MBA, chief executive officer of Aureus Health Services, discusses the evolving role of the mid-size specialty pharmacy.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Volume: 5
Number: 4
Conference Calendar
â—„        September 2014        â–º
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.